ClinicalTrials.gg
Not yet recruitingNCT07311317FLASHUpdated Dec 30, 2025

Cellular-Level Fluorescence Imaging for Intraoperative Margin Assessment in Breast Cancer

An observational study in Breast Cancer Early Stage Breast Cancer (Stage 1-3), sponsored by West China Hospital. Not yet recruiting at 3 sites in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by West China Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
165
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Breast Neoplasms by West China Hospital — 6 open to participants now, 6 under way, 1 of them phase 3. Breast Neoplasms · West China Hospital.

Started
2026
with 4 others
Observational
3 of 11
2 open now
Registered
7th of 11
by date

Among the 11 studies in Breast Neoplasms by West China Hospital, this one is one of 5 that started in 2026, is one of 3 observational ones, and was the 7th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 11 studies in Breast Neoplasms by West China Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Breast Neoplasms by West China Hospital, or all of them as a file.
02

Study summary

Accurate intraoperative margin assessment in breast cancer surgery remains challenging. Current reliance on frozen section pathology is limited by prolonged processing time, sampling constraints, and resource intensity, contributing to variable outcomes.

The EndoSCell Scanner is a novel cellular-resolution fluorescence-guided imaging technology designed to address these limitations. It enables real-time, pathology-level visualization of malignant cellular features at the surgical bed. With a 3mm probe allowing comprehensive 360° margin assessment, it reduces procedural time to under five minutes and may significantly lower secondary surgery rates.

This prospective, self-controlled study aims to evaluate the accuracy of the EndoSCell Scanner for intraoperative margin assessment in patients undergoing mastectomy. Its performance will be systematically compared against both frozen section and final paraffin pathology to validate sensitivity and operational efficiency. If proven effective, this technology could become a standard adjunct tool, standardizing precision in breast cancer surgery and improving patient outcomes by enhancing surgical consistency.

Read the detailed description

This study is a multicenter, prospective, self-controlled study. Basis for Sample Size Calculation: According to the results of the first phase, the accuracy of frozen pathology is 98.2%. Assuming that the detection interpretation results of ES are not inferior to intraoperative frozen pathology, a one-sided test will be conducted, with α=0.02, 1-β=0.8, and the non-inferiority margin is 0.02. The estimated required sample size is 593. Considering a 10% exclusion rate, the total sample size will be 659. Each patient is expected to have at least 4 samples taken, totaling 165 patients.

Data Collection:1)Basic patient information: age, gender; 2)Tumor diagnosis (including imaging diagnosis): location, size, and staging; 3)Intraoperative collected information: surgery start time, surgery end time; 4)Training and testing records of the physicians in the ES interpretation group; 5)Interpretation records: a.ES start time, ES interpretation end time, ES interpretation results, ES image satisfaction; b.Frozen pathology submission time, report receipt time, report results; c.Paraffin pathology submission time, report time, and report results.

The statistical analysis will be performed using SAS statistical software, version 9.4 or higher. All statistical tests will be two-sided. A P value less than or equal to 0.05 will be considered statistically significant. The description of quantitative indicators will include the mean, standard deviation, median, minimum, maximum, and interquartile range. The description of categorical indicators will use the number and percentage of each category. The comparison of general conditions between the two groups will be analyzed using appropriate methods based on the type of indicators. The consistency evaluation of quantitative data will use the Bland-Altman method and ICC.

03

Conditions studied

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Browse trials for

Keywords

  • Breast Cancer,
  • Fluorescence-guided
  • Cellular
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll 165 adult female patients scheduled to undergo breast surgery for histologically confirmed breast cancer. Eligible participants must provide written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 - 70 years
  • Patients scheduled for breast tumor resection
  • Clinically or radiologically showing a solitary lesion and

    1. (Before chemotherapy) Maximum tumor diameter ≤ 5cm;
    2. cN0-1;
    3. No clinical or imaging evidence of nipple, skin, chest wall invasion, or distant before surgery.
  • Subjects voluntarily sign or are exempted from signing upon approval by the ethics committee.

Exclusion criteria

Exclusion Criteria:

  • Inflammatory breast cancer;
  • Patients allergic to methylene blue and sodium fluorescein;
  • Unable to understand the trial requirements or unable to complete the study follow-up plan;
  • Pregnant and breastfeeding women;
  • Patients unable to complete follow-up due to mental illness, cognitive or emotional disorders;
  • Those with severe comorbidities (such as organ dysfunction, immune deficiency) or poor general condition;
  • Those participating in other clinical studies that may affect this trial;
  • Those for whom satisfactory specimens for both frozen pathology and paraffin pathology cannot be obtained during surgery;
  • Those who cannot obtain a paraffin pathology report.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
165 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. To evaluate the sensitivity and specificity of the EndoSCell Scanner (ES) detection, using paraffin pathology as the gold standard, in comparison to rapid frozen section (FS) pathology.

    Time frame: 3 month

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jan 2027, 12 months later.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 12 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 30, 2025
StartEst.
Jan 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07311317
Collaborators
Fourth People's Hospital of Sichuan Province
Responsible party
Du Zhenggui (deputy director of breast center, West China Hospital) — Principal investigator
First posted
Dec 30, 2025
Start date
Jan 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Dec 30, 2025

Study contacts

Zhenggui DU
Contact
docduzg@163.com
+86 13880768222

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion